Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Rhea-AI Summary

Enlivex (Nasdaq: ENLV) dosed the first U.S. patient in its global, randomized, double-blind, placebo-controlled Phase 2b trial of Allocetra for moderate-to-severe age-related primary knee osteoarthritis.

The study spans the United States, Denmark and Poland, with endpoints focused on pain, function, quality of life and mobility.

Positive

• First U.S. patient dosed in global Phase 2b Allocetra knee OA trial
• Trial supported by FDA IND clearance in March 2026 and DKMA approval in April 2026
• Multicenter, randomized, double-blind, placebo-controlled design across U.S., Denmark and Poland
• Key efficacy endpoints include pain and physical function at three and six months
• Enlivex cites prior Phase 1/2a data with robust and durable treatment effect in target population

Negative

• None.

News Market Reaction – ENLV

-3.23%

-3.23% Session close to close

In the May 18 session, ENLV declined 3.23%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement advances Enlivex’s clinical trajectory by dosing the first U.S. patient in its glo...

Analysis

This announcement advances Enlivex’s clinical trajectory by dosing the first U.S. patient in its global Phase 2b trial of Allocetra™ for age-related knee osteoarthritis, a condition impacting over 32 million Americans and projected to reach 78 million by 2040. The study’s randomized, double-blind, placebo-controlled design and three- and six-month pain and function endpoints will be key to watch. Investors may contextualize this progress alongside recent regulatory filings, capital structure developments, and the company’s dual clinical and crypto-treasury model.

Key Figures

US KOA prevalence: more than 32 million Americans Projected US KOA cases: 78 million Americans by 2040 Efficacy assessment period: three-month period +1 more

4 metrics

US KOA prevalence more than 32 million Americans Current burden of knee osteoarthritis mentioned in trial background

Projected US KOA cases 78 million Americans by 2040 Future prevalence projection for age-related knee osteoarthritis

Efficacy assessment period three-month period Key pain and function endpoint timing after Allocetra treatment

Efficacy assessment period six-month period Key pain and function endpoint timing after Allocetra treatment

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	RAIN listing update	Positive	+2.3%	RAIN treasury token listed on HTX, expanding liquidity and accessibility.
Apr 28	RAIN holdings update	Positive	-6.4%	Company detailed RAIN holdings value and discounted option exercise terms.
Apr 23	Allocetra data presentation	Positive	+2.0%	Phase IIa Allocetra data with significant pain reduction and improved function.
Apr 21	DKMA trial approval	Positive	+0.3%	Danish regulator approved Phase 2b Allocetra KOA trial participation.
Apr 08	Share tokenization	Positive	+12.0%	Launch of ENLVon tokenized shares enabling blockchain-based investor access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news-driven moves mostly aligned with positive announcements, with one notable divergence on a treasury update.

Recent Company History

Over the past months, Enlivex has combined clinical and digital-asset milestones. A RAIN token listing on HTX and a large RAIN treasury disclosure were paired with mixed stock reactions. Multiple releases highlighted Allocetra™ progress, including Phase IIa data at OARSI and Danish approval for the global Phase 2b KOA trial, each followed by modest gains. Tokenization of Enlivex shares via ENLVon coincided with a stronger move. Today’s first-patient dosing in the U.S. continues the Phase 2b execution narrative.

Key Terms

phase 2b, fda ind, randomized, double-blind, +4 more

8 terms

phase 2b medical

"Phase 2b clinical trial of Allocetra™ for the treatment of patients..."

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

fda ind regulatory

"follows FDA IND clearance received in March 2026 and Danish Medicines..."

An FDA IND (Investigational New Drug) application is the formal request that a drug developer files with the U.S. Food and Drug Administration to get permission to begin testing a new medicine in humans. Think of it as a regulatory “permission slip” that shows enough lab and safety data to justify clinical trials; for investors, IND clearance marks a major milestone that unlocks value-creating human studies and starts the timeline toward potential approval.

randomized medical

"global, multicenter, randomized, double-blind, placebo-controlled Phase 2b..."

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"global, multicenter, randomized, double-blind, placebo-controlled Phase 2b..."

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"global, multicenter, randomized, double-blind, placebo-controlled Phase 2b..."

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

intra-articular medical

"evaluate the efficacy and safety of intra-articular injections of Allocetra™..."

An intra-articular treatment is one that is injected directly into a joint space, such as the knee or shoulder, to deliver medication or therapy right where the problem is. For investors, this matters because intra-articular delivery can improve effectiveness and reduce systemic side effects compared with pills or injections elsewhere in the body, affecting a drug’s clinical value, regulatory pathway, market appeal, and reimbursement prospects.

osteoarthritis medical

"primary knee osteoarthritis (OA). The global, multicenter..."

A chronic joint condition in which the protective cushioning (cartilage) between bones gradually breaks down, causing pain, stiffness and reduced mobility—think of joints like shock absorbers that wear out over time. It matters to investors because it represents a large, predictable market for medicines, surgical devices and long‑term care; clinical trial results, regulatory decisions, reimbursement and new treatments can significantly affect sales, costs and valuation in healthcare-related companies.

quality-of-life medical

"Additional endpoints include changes in quality-of-life measures..."

Quality-of-life measures how a person’s everyday well-being and ability to function are affected by a disease or its treatment, covering symptoms, physical and mental functioning, and independence. For investors, these measures matter because better quality-of-life outcomes can drive regulatory approval, patient and doctor uptake, pricing power, and long-term sales—think of it as how a product improves customers’ daily lives, which determines demand and value over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026

Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA).

The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. The trial is enrolling patients from clinical centers in the United States, Denmark and Poland. Key efficacy endpoints include changes from baseline of pain and physical function compared with placebo, measured at three- and six-month periods following treatment. Additional endpoints include changes in quality-of-life measures and functional mobility assessments.

Oren Hershkovitz, Ph.D., CEO of Enlivex, commented, "Dosing the first patient in the United States marks a significant step in the execution of our global Phase 2b strategy for Allocetra™. The United States represents the largest clinical site network for this trial, and initiating enrollment there reflects the momentum we have built following FDA IND clearance and DKMA approval. Our Phase 1/2a data demonstrated a robust, durable, and clinically meaningful treatment effect in the patient population that is the center focus of this Phase 2b trial, and we believe that we are positioned to generate the data needed to move forward to the last stages of clinical development and offer a therapy that will address a significant unmet need for aging patients with this debilitating disease."

About Enlivex (Nasdaq: ENLV)

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

About Knee Osteoarthritis

Knee osteoarthritis (KOA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. There are currently no approved disease modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of knee OA patients are 60 years and older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com

FAQ

What did Enlivex (NASDAQ: ENLV) announce about its Phase 2b Allocetra trial on May 18, 2026?

Enlivex announced dosing of the first U.S. patient in its Phase 2b Allocetra trial for moderate-to-severe knee osteoarthritis. According to Enlivex, this marks a key step in its global strategy to assess efficacy and safety across multiple international clinical centers.

What is the design of Enlivex’s Phase 2b Allocetra trial for knee osteoarthritis (ENLV)?

The Allocetra Phase 2b trial is a global, multicenter, randomized, double-blind, placebo-controlled study. According to Enlivex, it evaluates intra-articular injections in patients with moderate-to-severe age-related primary knee osteoarthritis at sites in the United States, Denmark and Poland.

Which endpoints are being measured in Enlivex’s Phase 2b Allocetra knee osteoarthritis trial?

Key endpoints are changes from baseline in pain and physical function versus placebo at three and six months. According to Enlivex, additional endpoints include changes in quality-of-life measures and functional mobility assessments, aiming to capture broader patient benefits.

How do prior clinical results support Enlivex’s Phase 2b Allocetra trial in knee osteoarthritis?

Enlivex reports that Phase 1/2a data showed a robust, durable, clinically meaningful treatment effect in the same patient population. According to Enlivex, these earlier results underpin the Phase 2b design and its goal to advance Allocetra toward later-stage clinical development.

Where is Enlivex recruiting patients for the Phase 2b Allocetra trial in knee osteoarthritis?

Patients are being enrolled at clinical centers in the United States, Denmark and Poland. According to Enlivex, the United States represents the largest clinical site network in this Phase 2b program, reflecting momentum after FDA IND clearance and Danish regulatory approval.